DMKPQ (DMK Pharmaceuticals) Stock Based Compensation: $-0.25 Mil (TTM As of Sep. 2023)


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Stock Based Compensation?

DMK Pharmaceuticals DMKPQ -99.00% 16 Stock Based Compensation is $-0.25 Mil as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

DMK Pharmaceuticals's Stock Based Compensation for the three months ended in Sep. 2023 was $-0.05 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.25 Mil.

DMK Pharmaceuticals Stock Based Compensation Related Terms

DMK Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Stock Based Compensation Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.54 5.87 4.10 1.98 -0.34

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.33 0.07 0.05 -0.05
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

What does a Stock Based Compensation of $-0.25 Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Stock Based Compensation of $-0.25 Mil as of Sep. 2023. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Stock Based Compensation too high?
DMK Pharmaceuticals' current Stock Based Compensation is $-0.25 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Stock Based Compensation compare to CNNC and THCT?
DMK Pharmaceuticals' Stock Based Compensation of $-0.25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Stock Based Compensation is $-0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Stock Based Compensation of $-0.25 Mil. The current Stock Based Compensation is $-0.25 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Stock Based Compensation is $-0.25 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price